Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We employ our advanced, specialised process to create targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
P01127

UPID:
PDGFB_HUMAN

ALTERNATIVE NAMES:
PDGF-2; Platelet-derived growth factor B chain; Platelet-derived growth factor beta polypeptide; Proto-oncogene c-Sis

ALTERNATIVE UPACC:
P01127; G3XAG8; P78431; Q15354; Q6FHE7; Q9UF23

BACKGROUND:
The protein Platelet-derived growth factor subunit B, with alternative names such as PDGF-2 and c-Sis, is essential for embryonic development, cell growth, and the formation of blood vessels. It supports the proliferation and recruitment of pericytes and vascular smooth muscle cells, playing a key role in kidney glomeruli development and wound healing. Its signaling through heterodimer formation with PDGFA is crucial for its functions.

THERAPEUTIC SIGNIFICANCE:
Given its critical role in Basal ganglia calcification, idiopathic, 5, a disease marked by brain calcifications and neuropsychiatric symptoms, PDGF-B represents a promising target for drug discovery. Exploring PDGF-B's functions could lead to innovative treatments for this and potentially other diseases.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.